GOODERHAM, M.; SPELMAN, L.; IMAFUKU, S.; ROMANELLI, M.; MEROLA, J. F.; ARMSTRONG, A. W.; COLSTON, E.; BANERJEE, S.; SCHARNITZ, T.; BLAUVELT, A. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 4, p. s219, 2023. DOI: 10.25251/skin.7.supp.219. Disponível em: Acesso em: 16 jul. 2024.